FutureMeds

We are excited to introduce FutureMeds’ Promis of Progress: The Progress P.A.C.T. Built on 4 pillars: People, Access, Collaboration, and Truth, it is our company promise and guiding philosophy, designed to shape our interactions with patients, clients, partners, and our team. “𝙐𝙣𝙞𝙛𝙮𝙞𝙣𝙜 𝙨𝙞𝙩𝙚 𝙩𝙚𝙖𝙢𝙨 𝙖𝙘𝙧𝙤𝙨𝙨 𝙢𝙪𝙡𝙩𝙞𝙥𝙡𝙚 𝙘𝙤𝙪𝙣𝙩𝙧𝙞𝙚𝙨 𝙪𝙣𝙙𝙚𝙧 𝙤𝙣𝙚 𝙥𝙪𝙧𝙥𝙤𝙨𝙚 𝙝𝙖𝙨 𝙗𝙚𝙚𝙣 𝙖 𝙛𝙤𝙧𝙢𝙞𝙙𝙖𝙗𝙡𝙚 𝙩𝙖𝙨𝙠. 𝙒𝙚’𝙫𝙚 𝙨𝙥𝙚𝙣𝙩 𝙤𝙫𝙚𝙧 𝙩𝙬𝙤 𝙮𝙚𝙖𝙧𝙨 𝙘𝙧𝙚𝙖𝙩𝙞𝙣𝙜 𝙖 𝙫𝙖𝙡𝙪𝙚 𝙨𝙮𝙨𝙩𝙚𝙢 𝙩𝙝𝙖𝙩 𝙖𝙡𝙞𝙜𝙣𝙨 𝙥𝙚𝙧𝙛𝙚𝙘𝙩𝙡𝙮 𝙬𝙞𝙩𝙝 𝙤𝙪𝙧 𝙢𝙞𝙨𝙨𝙞𝙤𝙣 𝙤𝙛 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙞𝙣𝙜 𝙛𝙪𝙩𝙪𝙧𝙚 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚𝙨 𝙩𝙤 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨,” added Radoslaw (Radek) Janiak, CEO 𝗣𝗲𝗼𝗽𝗹𝗲 𝗺𝗮𝗸𝗲 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 Clinical research depends on the dedication, commitment & compassion of people. 𝗔𝗰𝗰𝗲𝘀𝘀 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗮𝗹𝗹 We believe everyone deserves the opportunity to thrive. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝘀 Great things come from working together. 𝗧𝗿𝘂𝘁𝗵 𝗯𝘂𝗶𝗹𝗱𝘀 𝘁𝗿𝘂𝘀𝘁 We are committed to fostering an environment that promotes honesty. “𝙄 𝙝𝙖𝙫𝙚 𝙛𝙪𝙡𝙡 𝙘𝙤𝙣𝙛𝙞𝙙𝙚𝙣𝙘𝙚 𝙩𝙝𝙖𝙩 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝙋𝙧𝙤𝙜𝙧𝙚𝙨𝙨 𝙋.𝘼.𝘾.𝙏. 𝙖𝙣𝙙 𝙤𝙪𝙧 𝙩𝙚𝙖𝙢𝙨’ 𝙨𝙪𝙥𝙥𝙤𝙧𝙩, 𝙬𝙚 𝙬𝙞𝙡𝙡 𝙘𝙪𝙡𝙩𝙞𝙫𝙖𝙩𝙚 𝙖 𝙘𝙤𝙢𝙥𝙖𝙣𝙮 𝙘𝙪𝙡𝙩𝙪𝙧𝙚 𝙖𝙩 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨 𝙩𝙝𝙖𝙩 𝙘𝙖𝙣 𝙮𝙞𝙚𝙡𝙙 𝙨𝙞𝙜𝙣𝙞𝙛𝙞𝙘𝙖𝙣𝙩 𝙡𝙤𝙣𝙜-𝙩𝙚𝙧𝙢 𝙗𝙚𝙣𝙚𝙛𝙞𝙩𝙨 𝙛𝙤𝙧 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨, 𝙥𝙖𝙧𝙩𝙣𝙚𝙧𝙨 𝙖𝙣𝙙 𝙤𝙪𝙧 𝙩𝙚𝙖𝙢,” said Wojciech Szczepanik, Executive VP of Operations #ClinicalTrials #ClinicalResearch

What an incredible 2 days! Last week, our managers from FutureMeds Germany and FutureMeds @Home teams gathered in Berlin for an intensive training session on change management and organizational development. Facilitated by Willy C. Kriz, Marcin Wardaszko and Łukasz Więch, MD, MBA, the team engaged in dynamic discussions, interactive simulations, and insightful experience exchanges. "𝙒𝙚 𝙚𝙭𝙥𝙡𝙤𝙧𝙚𝙙 𝙣𝙚𝙬 𝙬𝙖𝙮𝙨 𝙩𝙤 𝙨𝙪𝙥𝙥𝙤𝙧𝙩 𝙤𝙪𝙧 𝙧𝙖𝙥𝙞𝙙 𝙜𝙧𝙤𝙬𝙩𝙝 𝙖𝙣𝙙 𝙣𝙖𝙫𝙞𝙜𝙖𝙩𝙚 𝙩𝙧𝙖𝙣𝙨𝙛𝙤𝙧𝙢𝙖𝙩𝙞𝙤𝙣 𝙘𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨," said Iwona Tongbhoyai, Chief Client Solutions Officer. "𝙊𝙪𝙧 𝙡𝙚𝙖𝙙𝙚𝙧𝙨 𝙞𝙣 𝙂𝙚𝙧𝙢𝙖𝙣𝙮 𝙖𝙧𝙚 𝙣𝙤𝙬 𝙗𝙚𝙩𝙩𝙚𝙧 𝙚𝙦𝙪𝙞𝙥𝙥𝙚𝙙 𝙩𝙤 𝙚𝙣𝙝𝙖𝙣𝙘𝙚 𝙤𝙪𝙧 𝙨𝙞𝙩𝙚 𝙣𝙚𝙩𝙬𝙤𝙧𝙠'𝙨 𝙜𝙧𝙤𝙬𝙩𝙝 𝙖𝙣𝙙 𝙙𝙧𝙞𝙫𝙚 𝙩𝙝𝙚 𝙚𝙭𝙥𝙖𝙣𝙨𝙞𝙤𝙣 𝙤𝙛 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨 @𝙃𝙤𝙢𝙚, 𝙤𝙪𝙧 𝘿𝘾𝙏 𝙨𝙤𝙡𝙪𝙩𝙞𝙤𝙣." A big thank you to Willy C. Kriz, Marcin Wardaszko and Łukasz Więch for delivering such impactful training to our teams in Germany. #ClinicalTrial #ClinicalResearch 

Our brand-new dedicated research site in Poland will open its doors in Gdynia later this year. "𝙏𝙝𝙚 𝙂𝙙𝙮𝙣𝙞𝙖 𝙨𝙞𝙩𝙚 𝙬𝙞𝙡𝙡 𝙗𝙚 𝙖𝙣 𝙚𝙭𝙘𝙚𝙡𝙡𝙚𝙣𝙩 𝙖𝙙𝙙𝙞𝙩𝙞𝙤𝙣 𝙩𝙤 𝙤𝙪𝙧 𝙘𝙖𝙥𝙖𝙗𝙞𝙡𝙞𝙩𝙞𝙚𝙨, 𝙘𝙤𝙢𝙥𝙡𝙚𝙢𝙚𝙣𝙩𝙞𝙣𝙜 𝙤𝙪𝙧 𝙧𝙚𝙖𝙘𝙝 𝙞𝙣 𝙋𝙤𝙡𝙖𝙣𝙙" says Dr Piotr Rozpondek, Managing Director at FutureMeds Poland  "𝙄𝙣 𝙂𝙙𝙮𝙣𝙞𝙖 𝙬𝙚 𝙞𝙣𝙩𝙚𝙣𝙙 𝙩𝙤 𝙘𝙤𝙤𝙥𝙚𝙧𝙖𝙩𝙚 𝙬𝙞𝙩𝙝 𝙖 𝙜𝙧𝙤𝙪𝙥 𝙤𝙛 𝙜𝙧𝙚𝙖𝙩 𝙋𝙄𝙨, 𝙬𝙝𝙞𝙘𝙝 𝙬𝙞𝙡𝙡 𝙖𝙡𝙡𝙤𝙬 𝙪𝙨 𝙩𝙤 𝙥𝙧𝙤𝙫𝙞𝙙𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙞𝙣 𝙣𝙤𝙧𝙩𝙝𝙚𝙧𝙣 𝙋𝙤𝙡𝙖𝙣𝙙 𝙬𝙞𝙩𝙝 𝙗𝙚𝙩𝙩𝙚𝙧 𝙖𝙘𝙘𝙚𝙨𝙨 𝙩𝙤 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙩𝙧𝙞𝙖𝙡𝙨."   Why Gdynia? + This port city on the Baltic Coast is part of the Trójmiasto ("Three-City") urban area, along with Gdańsk and Sopot, with a combined population of 877,000, providing a broad patient base for clinical trials in various therapeutic areas and indications. + From a logistical perspective, the city is well-connected by air, road, and sea, making it easily accessible for IMP.  + The area boasts a well-developed healthcare infrastructure with several modern hospitals and medical facilities we aim to establish close working relationships with. + The city is also home to skilled healthcare professionals, including doctors, nurses, and research coordinators experienced in conducting clinical trials.  #ClinicalResearch #ClinicalTrials 

Q2 saw another busy period for FutureMeds, as we focused on implementing our company culture.  "Unifying site teams across 6 countries and DCT teams across 18 countries under one flag and with one purpose is a formidable task. We spent over 2 years to create the right value system and guiding principles that suit our environment, resonate with the teams, and align perfectly with our purpose of delivering future medicines to patients," added Radoslaw (Radek) Janiak "With the internal roll-out well underway, now we are dedicating significant effort to creating a dynamic platform where our team can seamlessly collaborate, share best practices, and foster a can-do attitude, which is paramount in the rapidly evolving clinical research landscape."   As we turn the page on Q2, we look back on some of the highlights of our growing organisation: 𝗦𝗶𝘁𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿𝘀 𝗙𝗼𝗿𝘂𝗺: FutureMeds launched the initiative to foster knowledge sharing, collaboration, and continuous improvement among our directors. https://lnkd.in/eprDRmpE 𝗙𝗿𝗮𝗻𝗸𝗳𝘂𝗿𝘁 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲: To mark the opening of FutureMeds Frankfurt, our German team organised an exclusive conference that attracted an engaged audience. https://lnkd.in/e8MWhvPX 𝗦𝗲𝗻𝗶𝗼𝗿 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗶𝗻 𝗕𝗮𝗿𝗰𝗲𝗹𝗼𝗻𝗮:Over 3 days, our team explored strategies for aligning the multitude of stakeholders in clinical research to provide comprehensive solutions. https://lnkd.in/eV8hDbvn 𝟯 𝗣𝗲𝗮𝗸𝘀 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗨𝗞: Over 30 courageous members of FutureMeds embarked on the challenge, each confronting the elements to achieve a shared goal. https://lnkd.in/evQYsQFk 𝗗𝗖𝗧 𝗼𝗻 𝘀𝘁𝗮𝗴𝗲: Iwona Tongbhoyai and Nicole Bohrmann addressed DGPharMed's incredible attendees and delved into the day-to-day examples and tangible benefits of decentralised clinical trials in Europe. https://lnkd.in/ebJxZH6E 𝗙𝗗𝗔 𝗜𝗻𝘀𝗽𝗲𝗰𝘁𝗶𝗼𝗻: FutureMeds Krakow underwent a successful FDA inspection towards the end of March. https://lnkd.in/ep5CGhjc We’re grateful for our team, partners, peers and clients, who are a key part of our journey.   Thank you! #ClinicalResearch #ClinicalTrials

FutureMeds launched a new initiative earlier this month: the Site Directors' Forum Spearheaded by Wojciech Szczepanik, EVP of Operations, it aims to foster knowledge sharing, collaboration, and continuous improvement among our experienced and talented site directors. “𝙏𝙝𝙚 𝙎𝙞𝙩𝙚 𝘿𝙞𝙧𝙚𝙘𝙩𝙤𝙧’𝙨 𝙁𝙤𝙧𝙪𝙢 𝙞𝙨 𝙤𝙣𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙢𝙤𝙨𝙩 𝙞𝙢𝙥𝙤𝙧𝙩𝙖𝙣𝙩 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨 𝙛𝙤𝙧 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨 𝙩𝙝𝙞𝙨 𝙮𝙚𝙖𝙧. 𝙄𝙩 𝙝𝙚𝙡𝙥𝙨 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨 𝙖𝙙𝙙𝙧𝙚𝙨𝙨 𝙩𝙝𝙚 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙞𝙣𝙜 𝙘𝙤𝙢𝙥𝙡𝙚𝙭𝙞𝙩𝙮 𝙤𝙛 𝙤𝙥𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙨, 𝙥𝙧𝙞𝙤𝙧𝙞𝙩𝙞𝙨𝙚 𝙩𝙝𝙚 𝙜𝙧𝙤𝙬𝙞𝙣𝙜 𝙣𝙪𝙢𝙗𝙚𝙧 𝙤𝙛 𝙣𝙚𝙬 𝙞𝙣𝙞𝙩𝙞𝙖𝙩𝙞𝙫𝙚𝙨 𝙖𝙣𝙙 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚 𝙘𝙤𝙡𝙡𝙖𝙗𝙤𝙧𝙖𝙩𝙞𝙤𝙣 𝙖𝙘𝙧𝙤𝙨𝙨 𝙤𝙪𝙧 𝙨𝙞𝙩𝙚𝙨 𝙖𝙣𝙙 𝙘𝙤𝙪𝙣𝙩𝙧𝙞𝙚𝙨.“ commented Wojciech Szczepanik Our first meeting, held at a historic farm-turned-hotel in Wrocław, featured thematic workshops and team-building activities, setting the stage for stronger collaboration. We look forward to the Site Directors’ Forum’s continuous growth and positive impact, enhancing our ability to deliver even higher-quality trials and better patient outcomes. #ClinicalTrials #ClinicalResearch P.S. To learn more visit our website: https://lnkd.in/eB363ybH

To mark the opening of FutureMeds Frankfurt, our German team organised an exclusive conference on Wednesday. It attracted a diverse group of stakeholders and explored how dedicated research sites, decentralised trial solutions, and digital recruitment can drive meaningful, lasting change in research.  “𝙂𝙚𝙧𝙢𝙖𝙣𝙮 𝙖𝙨 𝙖 𝙨𝙩𝙪𝙙𝙮 𝙡𝙤𝙘𝙖𝙩𝙞𝙤𝙣 𝙞𝙨 𝙚𝙨𝙥𝙚𝙘𝙞𝙖𝙡𝙡𝙮 𝙘𝙡𝙤𝙨𝙚 𝙩𝙤 𝙢𝙮 𝙝𝙚𝙖𝙧𝙩, 𝙖𝙣𝙙 𝙄 𝙬𝙖𝙨 𝙩𝙝𝙧𝙞𝙡𝙡𝙚𝙙 𝙩𝙤 𝙨𝙚𝙚 𝙩𝙝𝙚 𝙧𝙞𝙘𝙝 𝙚𝙭𝙘𝙝𝙖𝙣𝙜𝙚 𝙤𝙛 𝙞𝙙𝙚𝙖𝙨 𝙗𝙚𝙩𝙬𝙚𝙚𝙣 𝙨𝙩𝙪𝙙𝙮 𝙨𝙞𝙩𝙚𝙨, 𝘾𝙍𝙊𝙨, 𝙨𝙥𝙤𝙣𝙨𝙤𝙧𝙨, 𝙖𝙣𝙙 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙘𝙤𝙢𝙥𝙖𝙣𝙞𝙚𝙨,” added Ninon Armbrust, Head of Sites at FutureMeds Germany  “𝙏𝙝𝙚 𝙛𝙚𝙚𝙙𝙗𝙖𝙘𝙠 𝙬𝙚 𝙧𝙚𝙘𝙚𝙞𝙫𝙚𝙙 𝙬𝙖𝙨 𝙤𝙪𝙩𝙨𝙩𝙖𝙣𝙙𝙞𝙣𝙜, 𝙖𝙣𝙙 𝙞𝙩’𝙨 𝙧𝙚𝙬𝙖𝙧𝙙𝙞𝙣𝙜 𝙩𝙤 𝙝𝙚𝙖𝙧 𝙝𝙤𝙬 𝙢𝙪𝙘𝙝 𝙚𝙫𝙚𝙧𝙮𝙤𝙣𝙚 𝙫𝙖𝙡𝙪𝙚𝙙 𝙩𝙝𝙚 𝙙𝙞𝙨𝙘𝙪𝙨𝙨𝙞𝙤𝙣𝙨 𝙖𝙣𝙙 𝙥𝙧𝙚𝙨𝙚𝙣𝙩𝙖𝙩𝙞𝙤𝙣𝙨.” After the conference, the guests and team gathered at the new Frankfurt site for the ribbon-cutting ceremony. “𝘽𝙪𝙞𝙡𝙙𝙞𝙣𝙜 𝙤𝙣 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨’ 𝙖𝙣𝙙 𝙤𝙪𝙧 𝘽𝙚𝙧𝙡𝙞𝙣’𝙨 𝙨𝙞𝙩𝙚 𝙧𝙚𝙥𝙪𝙩𝙖𝙩𝙞𝙤𝙣, 𝙚𝙭𝙥𝙚𝙧𝙞𝙚𝙣𝙘𝙚 𝙖𝙣𝙙 𝙤𝙪𝙩𝙨𝙩𝙖𝙣𝙙𝙞𝙣𝙜 𝙨𝙩𝙖𝙣𝙙𝙖𝙧𝙙 𝙤𝙛 𝙦𝙪𝙖𝙡𝙞𝙩𝙮, 𝙤𝙥𝙚𝙣𝙞𝙣𝙜 𝙖 𝙨𝙚𝙘𝙤𝙣𝙙 𝙨𝙞𝙩𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙍𝙝𝙚𝙞𝙣-𝙈𝙖𝙞𝙣, 𝙖 𝙬𝙤𝙧𝙡𝙙-𝙡𝙚𝙖𝙙𝙞𝙣𝙜 𝙡𝙞𝙛𝙚 𝙨𝙘𝙞𝙚𝙣𝙘𝙚𝙨 𝙘𝙡𝙪𝙨𝙩𝙚𝙧, 𝙢𝙖𝙙𝙚 𝙥𝙚𝙧𝙛𝙚𝙘𝙩 𝙨𝙚𝙣𝙨𝙚,” commented Dr Radoslaw (Radek) Janiak, CEO at FutureMeds “𝙊𝙥𝙚𝙧𝙖𝙩𝙞𝙣𝙜 𝙞𝙣 𝙩𝙝𝙚 𝙧𝙚𝙜𝙞𝙤𝙣 𝙬𝙞𝙡𝙡 𝙚𝙣𝙖𝙗𝙡𝙚 𝙁𝙪𝙩𝙪𝙧𝙚𝙈𝙚𝙙𝙨 𝙩𝙤 𝙗𝙪𝙞𝙡𝙙 𝙨𝙩𝙧𝙤𝙣𝙜𝙚𝙧 𝙩𝙞𝙚𝙨 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝙡𝙤𝙘𝙖𝙡 𝙞𝙣𝙙𝙪𝙨𝙩𝙧𝙮 𝙖𝙣𝙙 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩 𝙖𝙘𝙘𝙚𝙨𝙨 𝙩𝙤 𝙣𝙚𝙬 𝙩𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨.” Thank you to all of our guests from Alcedis - a HUMA company, ARTIMED Medical Consulting GmbH, Boehringer Ingelheim CSL, Clivolution GmbH, Eurofins bioskin GmbH, FGK Clinical Research GmbH, ICON plc, ICRC-Weyer GmbH, IQVIA, LinkMedical GmbH, MLM Medical Labs, PPD Germany GmbH, PSI CRO AG, SGS Analytics Germany GmbH, Sanofi, Takeda Pharma Vertrieb GmbH & Co KG, Weleda AG, selectION Therapeutics for joining us. Special thanks to Dr. Peter Hahn, Dr Kerstin Sturm, Doris Wiegel and Dr. Oliver Deuster for sharing their views and insights with us. And as always, a big thank you to Ninon and her team for organising such a rewarding event. #ClinicalResearch #ClinicalTrials P.S. Learn more here: https://lnkd.in/eap7HaNc

PCMG Assembly 2024 was an outstanding event bringing together industry leaders and professionals in the sunny Netherlands.   FutureMeds’ Cameron Glen and Nachiket Chandak certainly made the most of it.     Nach moderated the Tipping Point or Tripping Point panel discussion and explored the evolving role of the Outsourcing Manager. Both took advantage of the networking opportunities to build relationships with industry professionals. They also engaged in discussions about AI's impact. Striking the right balance between technology and human connections is a challenge many of us are contemplating today.   Kudos to PCMG Clinical Outsourcing Community for creating such an enriching experience.    #ClinicalTrials #ClinicalResearch 𝗣.𝗦. Cameron and Nach are off to Frankfurt for the site opening and conference organised by Ninon Armbrust and the fantastic FutureMeds Germany team. You can find more about it here: https://lnkd.in/e_ZhpUHd

Plenary session Tipping Point or Tripping Point moderated by our very own Nachiket Chandak discussing the evolving role of the Outsourcing Manager. #PCMG FutureMeds

FutureMeds’ Senior Management Team convened for a three-day meeting in sunny Barcelona to 🎯 discuss strategies for aligning the multitude of stakeholders in clinical research. In addition to the growing influence of patients, sponsors and CROs are increasingly decentralising the development of their clinical trial infrastructures across different geographies and functions. As the number of decision-makers expands, providing comprehensive solutions at the clinical trial level becomes more challenging. “𝙄𝙣𝙨𝙩𝙚𝙖𝙙 𝙤𝙛 𝙢𝙚𝙧𝙚𝙡𝙮 𝙗𝙧𝙚𝙖𝙠𝙞𝙣𝙜 𝙙𝙤𝙬𝙣 𝙖𝙛𝙛𝙞𝙡𝙞𝙖𝙩𝙚-𝙗𝙖𝙨𝙚𝙙 𝙗𝙤𝙪𝙣𝙙𝙖𝙧𝙞𝙚𝙨, 𝙬𝙚 𝙛𝙞𝙧𝙢𝙡𝙮 𝙗𝙚𝙡𝙞𝙚𝙫𝙚 𝙩𝙝𝙖𝙩 𝙝𝙚𝙡𝙥𝙞𝙣𝙜 𝙩𝙤 𝙞𝙣𝙩𝙚𝙜𝙧𝙖𝙩𝙚 𝙡𝙤𝙘𝙖𝙡 𝙖𝙣𝙙 𝙜𝙡𝙤𝙗𝙖𝙡 𝙘𝙪𝙨𝙩𝙤𝙢𝙚𝙧 𝙨𝙩𝙖𝙠𝙚𝙝𝙤𝙡𝙙𝙚𝙧𝙨 𝙞𝙣𝙩𝙤 𝙘𝙧𝙞𝙩𝙞𝙘𝙖𝙡 𝙙𝙚𝙘𝙞𝙨𝙞𝙤𝙣-𝙢𝙖𝙠𝙞𝙣𝙜 𝙥𝙧𝙤𝙘𝙚𝙨𝙨𝙚𝙨 𝙬𝙞𝙡𝙡 𝙚𝙣𝙝𝙖𝙣𝙘𝙚 𝙩𝙝𝙚 𝙖𝙘𝙘𝙚𝙥𝙩𝙖𝙣𝙘𝙚 𝙤𝙛 𝙞𝙣𝙩𝙚𝙧𝙣𝙖𝙩𝙞𝙤𝙣𝙖𝙡 𝙨𝙞𝙩𝙚 𝙖𝙣𝙙 𝙥𝙖𝙩𝙞𝙚𝙣𝙩 𝙨𝙤𝙪𝙧𝙘𝙞𝙣𝙜 𝙨𝙤𝙡𝙪𝙩𝙞𝙤𝙣𝙨” commented Dr Torsten Sernau, MD Sernau, VP of Medical Operations. "𝘽𝙮 𝙝𝙖𝙧𝙣𝙚𝙨𝙨𝙞𝙣𝙜 𝙩𝙝𝙚 𝙘𝙤𝙢𝙗𝙞𝙣𝙚𝙙 𝙞𝙣𝙛𝙡𝙪𝙚𝙣𝙘𝙚 𝙤𝙛 𝙡𝙤𝙘𝙖𝙡 𝙖𝙣𝙙 𝙜𝙡𝙤𝙗𝙖𝙡 𝙨𝙥𝙤𝙣𝙨𝙤𝙧 𝙩𝙚𝙖𝙢𝙨, 𝘾𝙍𝙊 𝙧𝙚𝙥𝙧𝙚𝙨𝙚𝙣𝙩𝙖𝙩𝙞𝙫𝙚𝙨, 𝙨𝙞𝙩𝙚 𝙣𝙚𝙩𝙬𝙤𝙧𝙠 𝙥𝙧𝙤𝙛𝙚𝙨𝙨𝙞𝙤𝙣𝙖𝙡𝙨, 𝙖𝙣𝙙, 𝙞𝙢𝙥𝙤𝙧𝙩𝙖𝙣𝙩𝙡𝙮, 𝙩𝙝𝙚 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙩𝙝𝙚𝙢𝙨𝙚𝙡𝙫𝙚𝙨, 𝙬𝙚 𝙘𝙖𝙣 𝙨𝙞𝙜𝙣𝙞𝙛𝙞𝙘𝙖𝙣𝙩𝙡𝙮 𝙞𝙢𝙥𝙧𝙤𝙫𝙚 𝙩𝙝𝙚 𝙚𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚𝙣𝙚𝙨𝙨 𝙤𝙛 𝙤𝙪𝙧 𝙩𝙧𝙞𝙖𝙡 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙮 𝙨𝙤𝙡𝙪𝙩𝙞𝙤𝙣𝙨." The trip also provided a unique opportunity for our senior management team to get to know each other better and bond over shared experiences. “𝙒𝙚 𝙞𝙣𝙙𝙪𝙡𝙜𝙚𝙙 𝙞𝙣 𝙚𝙭𝙘𝙚𝙡𝙡𝙚𝙣𝙩 𝙨𝙚𝙖𝙛𝙤𝙤𝙙, 𝙥𝙖𝙧𝙩𝙞𝙘𝙞𝙥𝙖𝙩𝙚𝙙 𝙞𝙣 𝘾𝙖𝙩𝙖𝙡𝙖𝙣 𝙬𝙞𝙣𝙚 𝙩𝙖𝙨𝙩𝙞𝙣𝙜𝙨, 𝙖𝙣𝙙 𝙚𝙭𝙥𝙡𝙤𝙧𝙚𝙙 𝙩𝙝𝙚 𝙧𝙚𝙢𝙖𝙧𝙠𝙖𝙗𝙡𝙚 𝙎𝙖𝙣𝙩 𝙋𝙖𝙪 𝙃𝙤𝙨𝙥𝙞𝙩𝙖𝙡, 𝙬𝙝𝙞𝙘𝙝 𝙬𝙖𝙨 𝙙𝙚𝙘𝙡𝙖𝙧𝙚𝙙 𝙖 𝙒𝙤𝙧𝙡𝙙 𝙃𝙚𝙧𝙞𝙩𝙖𝙜𝙚 𝙨𝙞𝙩𝙚 𝙗𝙮 𝙐𝙉𝙀𝙎𝘾𝙊 𝙞𝙣 1997.” “𝙏𝙝𝙚 𝙚𝙭𝙥𝙚𝙧𝙞𝙚𝙣𝙘𝙚 𝙡𝙚𝙛𝙩 𝙪𝙨 𝙞𝙣𝙨𝙥𝙞𝙧𝙚𝙙 𝙖𝙣𝙙 𝙚𝙖𝙜𝙚𝙧 𝙩𝙤 𝙖𝙥𝙥𝙡𝙮 𝙤𝙪𝙧 𝙣𝙚𝙬𝙛𝙤𝙪𝙣𝙙 𝙠𝙣𝙤𝙬𝙡𝙚𝙙𝙜𝙚 𝙖𝙣𝙙 𝙞𝙣𝙨𝙞𝙜𝙝𝙩𝙨 𝙩𝙤 𝙤𝙪𝙧 𝙬𝙤𝙧𝙠.” #ClinicalTrials #ClinicalResearch 

Did you know that close to 45% of physicians and about 24% of nurses in Germany are nearing retirement? (WHO Report 2020) This looming crisis could drastically impact patient care and pose significant clinical trial capacity challenges in the country. As a clinical research site network aiming to accelerate patients' access to new treatments, both topics are close to our hearts. To mark the opening of FutureMeds Frankfurt, our German team is organising an exclusive conference to explore (amongst other topics) + The present and future of clinical trials in Germany + The vital role of dedicated research sites + How innovative solutions and DCT can alleviate constraints "𝙒𝙚 𝙡𝙤𝙤𝙠 𝙛𝙤𝙧𝙬𝙖𝙧𝙙 𝙩𝙤 𝙨𝙚𝙚𝙞𝙣𝙜 𝙮𝙤𝙪 𝙖𝙩 𝙩𝙝𝙚 𝙘𝙤𝙣𝙛𝙚𝙧𝙚𝙣𝙘𝙚 & 𝙨𝙞𝙩𝙚 𝙤𝙥𝙚𝙣𝙞𝙣𝙜 𝙖𝙣𝙙 𝙙𝙞𝙨𝙘𝙪𝙨𝙨𝙞𝙣𝙜 𝙠𝙚𝙮 𝙂𝙚𝙧𝙢𝙖𝙣 𝙩𝙧𝙞𝙖𝙡 𝙩𝙤𝙥𝙞𝙘𝙨 𝙩𝙝𝙧𝙤𝙪𝙜𝙝𝙤𝙪𝙩 𝙩𝙝𝙚 𝙙𝙖𝙮." - Ninon Armbrust, Head of Sites Register today: https://lnkd.in/eu6Cz8-E #ClinicalTrials #ClinicalResearch